NCT06656390 2026-03-06A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid TumorsShanghai Allink Biotherapeutics Co., Ltd.Phase 1/2 Recruiting202 enrolled